Sernova Corp., of London, Ontario, is taking islet cell transplantation to the next level by combining transplanted insulin-producing islet cells with its Cell Pouch device in a Phase I/II trial in patients with Type I diabetes. Read More
Condoms aside, contraception is still mainly the responsibility of women. Partly, that has biological reasons, since when contraception goes wrong, the resulting decisions and consequences fall disproportionately on women. But "there is a pressing need for male contraception," James Bradner told BioWorld Today. Read More
Two weeks after Idenix Pharmaceuticals Inc. regained global development and commercialization rights to its hepatitis C virus (HCV) candidates after the dissolution of its development and commercialization agreement with Novartis AG, the FDA placed IDX184, a nucleotide polymerase inhibitor, on a partial clinical hold. Read More
• Neuralstem Inc., of Rockville, Md., said the overallotment option of 900,000 additional common shares, at 40 cents apiece, was exercised in full in connection with its underwritten public offering, bringing total gross proceeds to $2.8 million. Read More
• DARA BioSciences Inc., of Raleigh, N.C., said it entered an exclusive distribution agreement with Seyer Pharmatec Inc., of Guaynabo, Puerto Rico, for the sale and distribution of Soltamax (tamoxifen citrate, oral solution) in the Commonwealth of Puerto Rico. Read More
• Lexicon Pharmaceuticals Inc., of The Woodlands, Texas, reported preliminary results from a Phase I dose-ranging study of LX2931, an inhibitor of sphingosine-1-phosphate lyase, in rheumatoid arthritis. The compound was well tolerated at all doses evaluated, with no serious adverse events. Read More
